Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iodixanol
Drug ID BADD_D01178
Description Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
Indications and Usage Iodixanol is a contrast agent during coronary angiography.
Marketing Status approved
ATC Code V08AB09
DrugBank ID DB01249
KEGG ID D01474
MeSH ID C044834
PubChem ID 3724
TTD Drug ID D0Y4YG
NDC Product Code 71806-222; 65219-381; 0407-2223; 65219-383; 0407-2222; 57884-0029
UNII HW8W27HTXX
Synonyms iodixanol | Visipaque | Visipaque Unique Softpac | iodixanol-320 | contrast media 2-5410-3
Chemical Information
Molecular Formula C35H44I6N6O15
CAS Registry Number 92339-11-2
SMILES CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(= C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nasal obstruction22.12.03.0130.007113%Not Available
Nausea07.01.07.0010.327927%
Nephropathy20.05.03.0010.007113%Not Available
Nephropathy toxic20.05.03.002; 12.03.01.0100.099587%Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Nodal rhythm02.03.03.0210.007113%Not Available
Non-cardiogenic pulmonary oedema24.03.08.004; 22.01.03.006--Not Available
Ocular hyperaemia06.04.05.0040.014227%Not Available
Odynophagia07.01.06.0360.010670%Not Available
Oedema14.05.06.010; 08.01.07.0060.028454%Not Available
Oedema mucosal08.01.06.0120.007113%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oesophagitis07.08.05.001--
Pain08.01.08.004--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.028454%Not Available
Palpitations02.11.04.0120.046237%
Papule23.03.03.0380.014227%Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Parosmia22.04.03.007; 17.04.04.002--Not Available
Periorbital oedema23.04.01.002; 06.08.03.017; 10.01.05.0100.007113%
Peripheral ischaemia24.04.03.002--
Petechiae23.06.01.003; 01.01.03.002; 24.07.06.0040.007113%Not Available
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.028454%Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pneumothorax22.05.02.0030.010670%
Polymyalgia rheumatica15.06.01.001; 10.04.05.003--Not Available
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.0090.017783%
Productive cough22.02.03.0050.010670%
Pruritus23.03.12.0011.006544%
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene